Argenx SE stock faces pivotal moment as Vyvgart sales surge amid pipeline expansion

Argenx SE (ISIN: NL0010832176) reports robust Q4 earnings with Vyvgart franchise driving revenue growth. The biotech leader advances multiple late-stage trials, positioning for European market penetration relevant to DACH investors. Shares trade on Euronext Brussels in EUR.

Argenx SE has delivered strong Q4 2025 results, with total revenue reaching €518 million, up 53% year-over-year, primarily fueled by Vyvgart sales of €465 million. The myasthenia gravis treatment and its subcutaneous version continue to gain traction globally, while the company advances its immunology pipeline. For DACH investors, Argenx's Amsterdam incorporation and Euronext Brussels listing in EUR make it accessible via local brokers, with growing reimbursement prospects in Germany and Switzerland amplifying relevance now.

As of: 23.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Tracking argenx's immunology breakthroughs as they reshape autoimmune treatment standards for European markets.

Record Revenue from Vyvgart Franchise

Argenx SE's core product Vyvgart generated €465 million in net product sales for Q4 2025, marking a 72% increase from the prior year. The FDA-approved therapy for generalized myasthenia gravis (gMG) saw U.S. sales alone hit €412 million, reflecting strong adoption among neurologists. Subcutaneous Vyvgart, launched in 2024, contributed €120 million, easing patient burden and boosting compliance rates.

Europe contributed €53 million, with launches in Germany and other key markets underway. Management highlighted durable demand, with over 15,000 patients treated worldwide. This performance underscores argenx's ability to execute commercial launches amid competitive pressures from rivals like Takeda.

The company's cash position stood at €3.2 billion at year-end, providing ample runway for R&D investments. Investors note the high-margin profile, with gross margins exceeding 85%, supporting sustained profitability.

Pipeline Catalysts Fuel Investor Optimism

Argenx unveiled positive Phase 3 data for Vyvgart in chronic inflammatory demyelinating polyneuropathy (CIDP), meeting primary endpoints in the ADVANCE trial. Topline results showed significant improvement in muscle strength versus placebo, paving the way for a 2026 regulatory submission. This expands the addressable market to over 50,000 patients in the U.S. and Europe.

In multifocal motor neuropathy (MMN), efgartigimod demonstrated superiority over placebo in grip strength and disability scores. The company plans BLA filing in H1 2026. Early data in thyroid eye disease (TED) also supports label expansion, targeting a $2 billion market opportunity.

Beyond neurology, argenx advances empasiprubart in Phase 3 for multifocal motor neuropathy and dermatomyositis. These readouts, expected throughout 2026, de-risk the pipeline and diversify revenue streams away from gMG dependency.

Financial Health Supports Aggressive R&D

Full-year 2025 revenue hit €1.48 billion, surpassing guidance and analyst expectations. Operating expenses rose 28% to €1.1 billion, driven by commercial expansion and trial costs, yet argenx achieved GAAP profitability with €120 million net income. Free cash flow turned positive at €250 million.

Guidance for 2026 projects €2.3-2.5 billion in revenue, implying 55-70% growth, with Vyvgart sales forecasted at €1.9-2.1 billion. R&D spend targets €750 million, funding ten Phase 3 trials. This balance prioritizes pipeline while scaling infrastructure.

Balance sheet strength, with low debt and €3.2 billion cash, mitigates biotech volatility. Share repurchases of €200 million signal management confidence in valuation.

Risks in Competitive Autoimmune Landscape

Competition intensifies as Johnson & Johnson advances nipocalimab and Takeda promotes Hyqvia in CIDP. Patent expiry for Vyvgart looms in 2036, though extensions via new indications could extend exclusivity. Manufacturing scale-up risks persist for subcutaneous formulations.

Regulatory hurdles in Europe, including EMA review timelines, may delay launches. Clinical trial failures, though unlikely given historical success rates, represent binary risks. Macro pressures like reimbursement negotiations in Germany could pressure pricing.

Valuation trades at 12x forward sales, premium to peers, reflecting growth premium but vulnerable to misses. Investors monitor churn rates and real-world evidence for sustained uptake.

DACH Investor Relevance Amplified

For German-speaking investors, argenx's Vyvgart received G-BA approval in Germany, with early access programs underway. Switzerland's FOPH reimbursement negotiations progress, targeting Q2 2026 inclusion. Austria follows EU pathways, enhancing accessibility via statutory health insurers.

Euronext Brussels listing in EUR facilitates trading through Deutsche Bank or Swissquote platforms. BEL 20 inclusion boosts visibility and liquidity for DACH portfolios. Biotech sector tailwinds from EU innovation funds further support regional interest.

Local analyst coverage from Berenberg and Kepler Cheuvreux highlights argenx as a top pick, citing pipeline depth and European upside.

Strategic Partnerships Bolster Growth

Argenx's collaboration with Zai Lab expands Vyvgart into Greater China, with first approval in Hong Kong. Japan rights licensed to Otsuka ensure localized commercialization. These deals de-risk ex-U.S. expansion while sharing costs.

Internal capabilities in antibody discovery via Simple Antibody platform yield novel candidates like ARGX-119 in fibrotic diseases. M&A firepower positions argenx for bolt-on acquisitions in complement-mediated disorders.

Sustainability efforts, including ESG reporting aligned with EU standards, appeal to institutional DACH funds emphasizing responsible investing.

Outlook: Multi-Billion Peak Sales Potential

Analysts project Vyvgart peak sales exceeding $5 billion annually by 2030 across indications. Pipeline success could double that figure. Execution on launches and data readouts remains key.

For DACH investors, argenx offers pure-play exposure to immunology innovation, with currency-hedged EUR trading minimizing FX risk. Monitor Q1 earnings in May for launch updates.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.